Abatacept: all 220 studies that test it

Page 1 of 3. Open to participants first (30), then studies with results posted, then the rest; newest registration first within each.

• Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell DiseaseRecruitingNCT07616154Phase 2
• Partial Stem Cell Transplant for Sickle Cell Disease From Matched DonorsRecruitingNCT07599176Phase 1/2
• Azacitidine and Abatacept in Relapsed or Refractory T-Cell LymphomaRecruitingNCT07388563Phase 1
• Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic MalignanciesRecruitingNCT07366801Phase 2/3
• Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched DonorRecruitingNCT07238712Phase 2
• Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingNCT07138898Phase 2
• Treatment of Antibody-Mediated Rejection (ABMR) With CarBelRecruitingNCT06918990Phase 1
• HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCTRecruitingNCT06731504Early Phase 1
• Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic ArthritisRecruitingNCT06654882Phase 3
• Belatacept in Heart TransplantationRecruitingNCT06478017Phase 2
• IL-2 Plus Abatacept in FTDRecruitingNCT06395038Phase 1
• Comparison of the Effects of Belatacept and Anticalcineurins on Endothelial Function in Renal Transplant Patients - <BELAFENDO>RecruitingNCT06291077Phase 4
• Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin InhibitorsNot yet recruitingNCT06279494Phase 1/2
• Advancing Transplantation Outcomes in ChildrenRecruitingNCT06055608Phase 2
• Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell TransplantationRecruitingNCT06008808Phase 1
• Assessment of Biomarker-Guided CNI Substitution In Kidney TransplantationRecruitingNCT05917522Phase 2
• Efficacy of a Sequential Treatment Strategy in Rheumatoid ArthritisRecruitingNCT05428488Phase 3
• Thal-Fabs: Reduced Toxicity Conditioning for High Risk ThalassemiaRecruitingNCT05426252Phase 1/2
• Abatacept in Immune Checkpoint Inhibitor MyocarditisRecruitingNCT05335928Phase 3
• Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)RecruitingNCT05289167Phase 1/2
• Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung DiseaseRecruitingNCT04925375Phase 2
• A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive MedicationsRecruitingNCT04877288Phase 3
• Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic ArthritisRecruitingNCT04610476Phase 3
• Belatacept in De Novo Heart TransplantationRecruitingNCT04477629Phase 2
• Abatacept for the Treatment of Giant Cell ArteritisRecruitingNCT04474847Phase 3
• Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease ProphylaxisRecruitingNCT04380740Phase 2
• Pilot Study: Interest of Belatacept as a Non-nephrotoxic Immunosuppressive Treatment in Cardiac Transplant Patients at Risk of Chronic Renal Failure (BELACOEUR)RecruitingNCT04180085Phase 2
• Treatment of Rheumatoid Arthritis With DMARDs: Predictors of ResponseRecruitingNCT03414502Phase 3
• Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate RespondersRecruitingNCT03227419Phase 4
• Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss TherapyRecruitingNCT02310867Phase 2
• Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ FunctionActive, not recruitingNCT06145282Phase 1/2Results posted
• Subcutaneous Abatacept in Renal Transplant RecipientsCompletedNCT05975450Phase 1Results posted
• Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy TrialCompletedNCT05822583Phase 4Results posted
• Use of DNA Testing to Help Transition Kidney Transplant Recipients to Belatacept-only ImmunosuppressionCompletedNCT04786067Phase 4Results posted
• Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory CompromiseTerminatedNCT04472494Phase 2Results posted
• Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid ArthritisCompletedNCT04186871Phase 2Results posted
• Immune Monitoring to Facilitate Belatacept MonotherapyCompletedNCT04177095Phase 4Results posted
• Treg Modulation With CD28 and IL-6 Receptor AntagonistsCompletedNCT04066114Phase 1/2Results posted
• A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney TransplantCompletedNCT04046549Phase 2Results posted
• A Study to Evaluate Biomarkers to Predict Efficacy of Abatacept in Rheumatoid ArthritisCompletedNCT03882008Phase 4Results posted
• Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)CompletedNCT03841357Phase 3Results posted
• A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different ProcessesCompletedNCT03714022Phase 1Results posted
• Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell TransplantationCompletedNCT03680092Phase 2Results posted
• Safety and Efficacy of Abatacept in IgG4-Related DiseaseCompletedNCT03669861Phase 2Results posted
• Rheumatoid Arthritis Memory B Cells and AbataceptCompletedNCT03652961Phase 4Results posted
• Effects of Abatacept on Myocarditis in Rheumatoid ArthritisTerminatedNCT03619876Phase 4Results posted
• Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to ChemotherapyTerminatedNCT03457142Phase 2Results posted
• Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung TransplantationCompletedNCT03388008Phase 2Results posted
• Abatacept for the Treatment of Myositis-associated Interstitial Lung DiseaseCompletedNCT03215927Phase 2Results posted
• A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens SyndromeCompletedNCT02915159Phase 3Results posted
• Abatacept in Juvenile DermatomyositisCompletedNCT02594735Phase 4Results posted
• Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)CompletedNCT02592798Phase 2Results posted
• Bela 8 Week DosingCompletedNCT02560558Phase 4Results posted
• Effects of Abatacept in Patients With Early Rheumatoid ArthritisCompletedNCT02504268Phase 3Results posted
• Abatacept for SLE Arthritis (IM101-330)TerminatedNCT02429934Phase 1/2Results posted
• Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or AbataceptTerminatedNCT02353780Phase 4Results posted
• Belatacept Conversion in Proteinuric Kidney Transplant RecipientsCompletedNCT02327403Phase 2Results posted
• Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)CompletedNCT02314403Phase 1Results posted
• Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical ApproachesCompletedNCT02270957Phase 2Results posted
• Treatment of Resistant Hypertension by Prevention of T-Cell Co-StimulationTerminatedNCT02232880Phase 2Results posted
• Belatacept 3 Month Post Transplant Conversion StudyCompletedNCT02213068Phase 4Results posted
• A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic SclerosisCompletedNCT02161406Phase 2Results posted
• Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant RecipientsCompletedNCT02152345Phase 4Results posted
• Regimen Optimization StudyCompletedNCT02137239Phase 2Results posted
• Switch From Calcineurin Inhibitor to Belatacept in Pancreas Transplant RecipientsCompletedNCT02103855Phase 4Results posted
• Study of Abatacept (Orencia) to Treat Primary Biliary CirrhosisCompletedNCT02078882Phase 4Results posted
• Efficacy of Belatacept in Reducing DSACompletedNCT02078193Phase 4Results posted
• An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia AreataCompletedNCT02018042Phase 2Results posted
• Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis VulgarisCompletedNCT01999868Phase 2Results posted
• Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)CompletedNCT01954979Phase 1/2Results posted
• Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309)CompletedNCT01953120Phase 4Results posted
• Belatacept Therapy for the Failing Renal AllograftCompletedNCT01921218Phase 3Results posted
• Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled SyringeCompletedNCT01890473Phase 1Results posted
• Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic ArthritisCompletedNCT01860976Phase 3Results posted
• Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive RegimenTerminatedNCT01856257Phase 2Results posted
• Methotrexate-Inadequate Response Autoinjector Device Sub StudyCompletedNCT01844895Phase 3Results posted
• Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)CompletedNCT01844518Phase 3Results posted
• Efficacy, Safety, Pharmacokinetics and Immunogenicity Study of Abatacept Administered Intravenously to Treat Active Polyarticular-course Juvenile Idiopathic Arthritis in JapanCompletedNCT01835470Phase 3Results posted
• A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-BasedCompletedNCT01820572Phase 3Results posted
• Pharmacokinetics, Safety and Tolerability of Single-dose Belatacept in Adolescent Kidney Transplant RecipientsCompletedNCT01791491Phase 2Results posted
• Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney TransplantationTerminatedNCT01790594Phase 2Results posted
• CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1CompletedNCT01773707Phase 2Results posted
• Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy VolunteersCompletedNCT01766050Phase 4Results posted
• Abatacept as GVHD Prophylaxis Phase 2CompletedNCT01743131Phase 2Results posted
• Belatacept Early Steroid Withdrawal TrialCompletedNCT01729494Phase 4Results posted
• Efficacy and Safety Study of Abatacept to Treat Lupus NephritisTerminatedNCT01714817Phase 3Results posted
• Pharmacokinetic Study to Compare the Blood Levels of Abatacept Manufactured at Lonza Biologics to the Blood Levels of Abatacept Manufactured at the Devens, Massachusetts (MA) Facility of Bristol-Myers SquibbCompletedNCT01439204Phase 1Results posted
• Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal TransplantationTerminatedNCT01436305Phase 2Results posted
• Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) PatientsCompletedNCT01351480Phase 3Results posted
• Ultrasound Scores as Indication of Response to Subcutaneous Abatacept in Subjects With Rheumatoid ArthritisCompletedNCT01299961Phase 3Results posted
• Abatacept in the Treatment of UveitisCompletedNCT01279954Phase 2Results posted
• Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid ArthritisCompletedNCT01142726Phase 3Results posted
• A Cooperative Clinical Study of Abatacept in Multiple SclerosisCompletedNCT01116427Phase 2Results posted
• Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCTCompletedNCT01012492Phase 2Results posted
• Substudy - Low Dose of Abatacept in Subjects With Rheumatoid ArthritisCompletedNCT00989235Phase 3Results posted
• Abatacept Versus Adalimumab Head-to-HeadCompletedNCT00929864Phase 3Results posted
• Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine TherapyCompletedNCT00886795Phase 1/2Results posted
• The Effect of Inhibition of B7-mediated Costimulation on Allergic Airway Inflammation in Mild Atopic AsthmaticsCompletedNCT00784459Phase 2Results posted
• Abatacept and Cyclophosphamide Combination Therapy for Lupus NephritisCompletedNCT00774852Phase 2Results posted
• A Rheumatoid Arthritis Study to Assess Early Response to Abatacept+MTX as Defined by Improvement of Synovitis Measures by Power Doppler UltrasonographyCompletedNCT00767325Phase 3Results posted

← Abatacept overview